Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy

wanglin72 enrolled

Overview

The purpose of this study is to evaluate the clinical safety and efficacy of QingReMoShen Granule to treat idiopathic membranous nephropathy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Idiopathic Membranous Nephropathy

Interventions

Losartan Tablets & QingReMoShen GranuleDRUG

Losartan Tablets & Placebo GranuleDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women and men who had a clinic and biopsy-proven idiopathic membranous nephropathy; * 6.0g≥24 hour urinary protein≥1.0g; * serum albumin concentration≥26g/L; * Chronic Kidney Disease (CKD)≤3 stage (eGFR\>30ml/min/1.73m2 MDRD); * Willing to participate in the trial and signed an informed consent. Exclusion Criteria: * Secondary membranous nephropathy; * Patients with one of the following circumstances- malignant tumors or malignancy, HIV infection, a history of mental illness, any serious systemic infection, serious gastrointestinal diseases, circulating hepatitis B surface antigens positive or persistent abnormal serum transaminase, abnormal glucose metabolism or diabetes mellitus; * Pregnant and lactating women; * Undergoing other clinical trials.

Locations (1)

Shanghai University of Traditional Chinese Medicine

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

24-hour urine protein

Time frame: At the 24thweek

Secondary Outcomes

serum albumin concentration

Time frame: At the 24thweek

eGFR

Time frame: At the 24thweek

Alanine transaminase

Time frame: At the 24thweek

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.